Myelofibrosis
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/�L) (PAC203)
- Details
ClinicalTrials.gov ID:
NCT03165734
Diagnosis Type:
NA
USOR Number:
- Address
1441 N Beckley Ave, Suite 102
Dallas, TX 75203
P: (214) 943-9911